Acurx Pharmaceuticals collaborates with Leiden University Medical Center to create innovative DNA Polymerase IIIC inhibitor antibiotics, targeting MRSA infections.

Acurx Pharmaceuticals has been granted a new patent for DNA Polymerase IIIC inhibitors, enhancing its portfolio in antibiotic development and treatment for severe bacterial infections.

Acurx Pharmaceuticals has been awarded a new patent for its cutting-edge DNA Polymerase IIIC inhibitors, strengthening its IP in antibiotic development.

Acurx Pharmaceuticals has been granted a new patent in India for its pioneering DNA Polymerase IIIC inhibitors aimed at tackling tough bacterial infections.

Acurx Pharmaceuticals has secured a new patent in Japan for DNA Polymerase IIIC inhibitors, advancing its innovative antibiotics targeting serious bacterial infections.